Say Goodbye to Post-Operation Nausea with this Phase III UK Trial Success

05/01/2016 - 3 minutes

An anti-vomiting medication for post-operative patients has smashed its phase III trial in the UK in one of the largest ever post-operation-nausea studies…ever. Roll on FDA approval.

acacia_pharma_emetic_PONV_phase_vomitAcacia Pharma is a Cambridge based clinical-stage biotech which looks to provide supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment.

One such angle of care involves reducing the nausea experienced after a patient goes through surgery, or the compulsive need to vomit when undergoing chemotherapy – both of which can have a dramatic toll on quality of life for patients. Acacia’s phase III trials for an anti-emetic, Baremsis, has therefore been offered as a potential preventative for such symptoms.

Currently two classes of anti-emetics are predominantly used to prevent post-operative nausea and vomiting (PONV) in these patients which is associated with the use of anaesthetic gases and opioid pain-killers (affecting up to 80% of high-risk patients).

Current prophylactic measures include 5HT3 antagonists (usually ondansetron) and corticosteroids (usually dexamethasone).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!